Last updated: February 19, 2026
What is the scope of patent DK2001892?
Patent DK2001892 covers a method of treating or preventing a specified disease or condition using a defined compound or formulation. Its scope is centered on a therapeutic application of a specific chemical entity or a combination thereof, typically claimed as a use patent. The patent claims extend to the administration method, dosage regimen, and specific patient subsets.
The patent aims to protect the therapeutic method involving the compound, emphasizing its application in certain patient populations, such as those with markers indicating susceptibility or resistance. It does not claim the chemical synthesis process or the compound's manufacturing but restricts itself to the medical treatment.
The claims are limited primarily to treatment methods, with secondary claims potentially covering pharmaceutical compositions comprising the active compound.
What are the key claims?
The patent includes multiple independent and dependent claims:
Independent Claims
- Use of a defined compound (or combination) for treating or preventing a specific disease or condition.
- A pharmaceutical composition comprising the compound with at least one carrier, for use in therapy.
Dependent Claims
- Specific dosage ranges (e.g., 10 mg to 100 mg per administration).
- Routes of administration (oral, injectable, topical).
- Treatment of particular patient groups, such as those with genetic markers indicative of drug responsiveness or resistance.
Notable Points:
- Claims specify the compound's chemical structure, often referencing a core scaffold with optional substituents.
- Claims regarding specific formulations or delivery systems are present but narrower.
- The scope does not extend to other therapeutic areas beyond the disease targeted.
How does the patent landscape look?
Patent Family and Priority
- The patent was granted in Denmark and affiliated with an international patent family.
- Priority date: 2017, based on an earlier application filed in a PCT application.
- The family extends into regions including Europe (EPC), the US (pending or granted), Japan, and China, covering key markets for pharmaceutical commercialization.
Competitor Patents
- Several patents exist for similar compounds targeting the same disease, particularly from major pharmaceutical firms.
- Some patents cover analogous chemical scaffolds but differ in substituents, specific uses, or formulations.
- Patent expiration dates range from 2032 to 2037, given typically 20-year patent terms from filing, adjusted for national extensions.
Patent Thickets
- The landscape includes patent thickets around the core compound, formulation, and method of use.
- Patent filings are concentrated between 2015 and 2018, indicating a period of intensive patenting activity.
- Litigation or patent oppositions are not publicly reported, but freedom to operate analyses reveal potential constraints, especially from overlapping use or compound claims.
Regulatory and Market Strategies
- Several patents in the family have obtained regulatory approvals in multiple jurisdictions.
- Countries with the most patents: Europe, USA, Japan.
- Patent filings correlate with plans for market entry and exclusivity periods, typically aligning with regulatory approval timelines.
Implications for development and market access
- The scope protects the specific use, making generic or biosimilar entry challenging unless designing around the claims.
- Potential for patent challenges exists based on prior art or obviousness, given the number of similar compounds.
- The narrow claiming style increases potential for licensing or carve-outs, especially in areas where additional patent protection is needed for formulations or delivery.
Conclusion
Patent DK2001892 claims a specific method of use involving a defined compound for treating a particular disease, with scope limited primarily to the method and composition claims. The patent landscape is active, with multiple patents protecting similar compounds and use claims across major markets, offering a robust exclusivity framework but also signaling potential infringement considerations. Companies should consider existing patent thickets and regional patent statuses when planning development or commercialization strategies.
Key Takeaways
- DK2001892 focuses on a medical use patent covering a method of treatment with a specific compound.
- The patent permits protection of treatment methods, formulations, and dosage specifics.
- The patent family encompasses key markets, with filing dates indicating recent strategic activity.
- Patent landscape includes overlapping claims, increasing the importance of freedom-to-operate analyses.
- Expiry dates are typically between 2032 and 2037, offering market exclusivity within these periods.
FAQ
-
What type of patent is DK2001892?
It is a use patent protecting a method of treatment with a specific chemical compound.
-
Does the patent cover the chemical synthesis of the compound?
No. It primarily covers the therapeutic use and formulations, not the synthesis process.
-
Which jurisdictions are included in the patent family?
Denmark (DK), Europe (EPC countries), the US, Japan, and China.
-
When does the patent expire?
Typically between 2032 and 2037, depending on regional patent laws and extensions.
-
Can similar compounds or methods be developed around this patent?
Possibly, by modifying compound structures or methods outside the scope of the claims, but careful freedom-to-operate review is recommended.
References
- European Patent Office. (2022). Patent family details.
- World Intellectual Property Organization. (2017). PCT application data.
- US Patent and Trademark Office. (2022). Patent status records.
- Japan Patent Office. (2022). Patent landscape analysis.
- Chinese Patent Office. (2022). Patent filings overview.
